Pharming Group (NASDAQ:PHAR - Get Free Report) rose 4.3% during trading on Wednesday . The company traded as high as $8.51 and last traded at $8.51. Approximately 1,346 shares were traded during trading, a decline of 79% from the average daily volume of 6,344 shares. The stock had previously closed at $8.16.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on PHAR shares. Oppenheimer increased their target price on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 20th.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Stock Up 0.7 %
The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The stock has a 50 day moving average of $8.50 and a 200 day moving average of $8.69. The firm has a market capitalization of $554.45 million, a price-to-earnings ratio of -31.35 and a beta of -0.08.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The business had revenue of $92.70 million for the quarter, compared to the consensus estimate of $76.67 million. As a group, analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
